Product Datasheet

ORIC-944

Catalog No. **BP-00084** · CAS **2369769-29-7** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Histone Methyltransferase	**Cancer**

Molecular formula	**$C_{26}H_{25}FN_6O$**
Molecular weight	**456.5147**

STRUCTURE



DESCRIPTION

ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

BIOLOGICAL ACTIVITY

In Vivo

Rinzimetostat (ORIC-944) (30, 100, 200 mg/kg; op; everyday for 50 days) induces significantly tumor regressions at all dose levels tested.

Rinzimetostat (ORIC-944) (30 mg/kg; op; everyday for 30 days) demonstrates strong single agent activity to enzalutamide in prostate cancer xenograft model.

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586.

[2]. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com
BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.
Lot CoA and SDS are separate documents.